deferasirox, chemical name 4-[3, 5-bis (2-hydroxyphenyl)-1,2, 4-triazole-1-yl] benzoic acid, is an iron chelating agent developed by Novartis, a Swiss pharmaceutical company, and is the first oral iron repellent approved by the United States FDA for routine use. It is approved for use in patients ≥2 years old with chronic iron overload caused by blood transfusion, and is recommended as the first-line drug in Europe for patients with thalassemia iron overload over 6 years old, and clinical studies are currently under way in China. Phase II and III clinical trials and pharmacokinetic studies have shown that it has good safety and tolerability, and can significantly reduce the iron load of the heart and liver, and is easy to be accepted by patients. At the same time, it also has anti-fungal (such as mucor growing in iron-rich environment), anti-cell proliferation, anti-malaria, anti-oxidative stress damage, anti-cytotoxic-induced apoptosis and other pharmacological properties. It can be used for the treatment of secondary hemochromatosis, porphyria cutis tarda and other diseases.